Showing posts with label SGO. Show all posts
Showing posts with label SGO. Show all posts

Tuesday, March 19, 2024

2024 Annual SGO Meeting Monday March 18, 2024


This was the final day of the 2024 SGO meeting.

I caught the tail end of the SGO Business meeting which included the passing of the gavel from this years President , Dr Angeles Alvarez-Secord to Dr Amanda Fader.

 

The next session, Doctor as Patient:Michael Frumovitz, MD,MPH,MS,CPXP was a moving presentation. Dr Frumovitz shared with his medical colleagues what his experience was as physician and  stage 3 pancreatic cancer patient. He mentioned how cancer patients run the gamut from those who are private to those who are public about their experiences.  


 
 
 
The Rapid Fire Poster Optimizing Surgery, Recovery and Survivorship followed.
 
Endometrial Cancer Assessment

 

 

 Heated IP chemotherapy (HIPEC)  during interval cytoreductive survery was associated with imporved survival.

 Criteria to determine need for ileostomy. 

Comparison of 2 drugs used to prevent venous thrombosis. 

Using Text messaging to measure PRO. 

Barriers to fertility preservation

Memory Impairment in post menopausal women was associated with increased age and comorbidity not chemotherapy. 

Another advocate presentation on peer support for Black women with endometrial cancer.  

 

The Fireside Chat: Critical Issues in Gyn Cancers and the Power of Shared Purpose panel included representatives from other gynecologic cancer organizations. They see the need to work together in many areas including improving recruitment of underrepresented peoples to clinical trials. I was pleased to see Annie Ellis, Patient Advocate and Survivor approach the mic at the end and share her thoughts. 

There was a moving tribute to former SGO President , Dr Wendy Brewster who passed away from pancreatic cancer. 

 Dr Secord gave her Presidential address. She certainly helped to grow SGO with now over 3000 members. 

 

Poster session 2 included the abstract that survivor/advocates Annie Ellis, Lynda Ryan, Adrienne Moore and I , submitted.   It was so exciting to have our abstract accepted for this poster session.


The final session I attended was Scientific Plenary V Late Breaking Abstract Session 2 .

Endometrial Cancer  

Another Patient presenting her experience in the DUO trial.

Ovarian Cancer Duo trial using Durvalumab , Bev and Olaparib

Chinese study of Niraparib maintenance and Individualized Dosing

The use of a P-53 reactivator in a PH 1 trial. 

 

Thanks SGO,  especially Dr Pothuri, Dr Powell and the entire planning committee for such a well run and informative meeting. Thanks again for going our of your way to including so many survivor-advocates in  important meeting presentations, on panels and presenting their posters.

Hope to see you next year in Seattle. 

Dee

Every Day is a Blessing! 

Posted by at No comments:
Labels: , , , , , , , , , , , , ,

Tuesday, March 12, 2024

Preparing For This Year's SGO Annual Meeting

I will be attending this year's SGO Annual Meeting virtually. It is being held in San Diego, March 15-March 18, 2024. On Friday, March 15th the 2024 Patient and Advocate Education Forum will also be held, in San Diego. The Forum is sponsored by the Foundation for Women's Cancer. I attended last year's forum and it was informative and allowed time to network with other patients , advocates and caregivers.

 


 

I received the link to the meeting app today so I started making my schedule and looking at sessions I'm interested in listening to. I will be posting on X using the #gyncsm from the sessions that occur in the main hall (F) as they occur live. Other segments of the meeting will be available for me to look at online after they are held and I will catch up on those after the meeting. 

I am happy to see many sessions include patient advocates including my friend Susan Leighton, presenting on Effectiveness of “Survivors Teaching Students®”: A patient-centered experiential educational model of ovarian cancer for rising healthcare professionals.  Thanks SGO and FWC!

I am also pleased to share that an abstract that Annie Ellis, Adrienne Moore, Linda Ryan and I submitted will be presented during the poster session on Monday, March 18th (Hall GH). I'll share more about that poster titled

Do it!': Gynecologic cancer clinical trial participants' advice to others and perspectives

on the day it is presented.

Here are some of the sessions I look forward to listening to:

Saturday

Scientific Plenary I: News We Can All Use 
  • Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: biomarker and subgroup analyses from the cervical, endometrial, and ovarian cancer cohorts of the DESTINY-PanTumor02 study
 
Scientific Plenary II: Moving the Needle Together  
  • Patient-Reported Outcome Results from Phase III MIRASOL Trial of mirvetuximab soravtansine vs. Investigator’s Choice of Chemotherapy in FRα Positive Platinum-resistant Ovarian Cancer 
  • Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial 
  •  A phase II/III study of cediranib and olaparib combination compared to cediranib or olaparib alone or standard of care chemotherapy, in platinum-resistant ovarian cancer (NRG-GY005)

Sunday

Presidential Invited Speaker: Erin Diehl: "F" Words at Work Supported by the Wellness Committee and N.E.D. 

Focused Plenary IV: CtDNA: Molecular Mirrors & Markers 

  • The Prognostic Value of Circulating Minimal Residual Disease in First-Line Treatment of Ovarian Cancer 
  • Utility of ctDNA as an early predictive biomarker of response to radiation in gynecologic malignancies 
  • Monitoring Minimal Residual Disease Using Circulating Tumor DNA in Patients Treated Long-Term with PARP Inhibitors for Ovarian Cancer 

Scientific Plenary IV: Late Breaking Abstract Session 1

  • Clinical activity of tazemetostat, an EZH2 inhibitor, among patients with advanced endometrioid endometrial cancer and ovarian clear cell carcinoma with and without ARID1A mutations (NRG-GY014)

Monday 

Doctor as a Patient: Michael M. Frumovitz, MD 

Tribute to Dr. Brewster – Stephanie Blank, MD, Amanda Nickles Fader, MD, S. Diane Yamada, MD, and Angeles Alvarez Secord, MD

Presidential Address: Angeles Alvarez-Secord, MD
 
Scientific Plenary V: Late Breaking Abstract Session 2 - The Turning Point Don't Be Left Out
 
 
Additional sessions I'll view online include those addressing disparities, ADCs( antibody drug conjugates), and clinical trial design. 
 
Now I just have to remember the three hour time difference so I don't miss any live sessions.

For those attending in person, please us #gyncsm in your posts on X so I can hear what you find valuable.  "See" you all next weekend.

Dee
Every Day is a Blessing!

 

Posted by at No comments:
Labels: , , , ,

Friday, September 15, 2023

Ten Years as a Community and Chat

On Wednesday, September 13th the #gyncsm Community celebrated it's Tenth Anniversary as a community and Chat.

It seems like yesterday when after taking part in a #bcsm chat on Recurrence I posted this to Twitter.  

 

Shortly after, Christina, a ovarian cancer advocate in Texas and I, an ovarian cancer survivor in New Jersey joined together to establish an online community. At first we were going to concentrate on ovarian cancer only but decided that our community should be open to all women diagnosed with gynecologic cancers. So the #gyncsm ( gyn cancer social media) community was born. 

We wanted to insure that the information and support we provided was accurate. We reached out to gynecologic oncologists,Dr D Dizon, Dr R Boulay, and Dr MJ Markham who agreed to be our first  Health Care Moderators. Knowing that we might chat about mental health issues or that some topics might cause emotional distress, we invited psychologist, Ann Becker-Schutte, Ph.D. to join us. As their practices and professional activities increased for our original HC Moderators, we were happy to have Sarah M. Temkin, MD and Shannon Westin, MD, MPH take the place of our original moderators. From the very first chat we have had the support of Cervivor, SGO and Dr Matthew Katz, who helped us draft our Tweet Disclaimer.

Our community has chatted about the risks and treatments of all the gyn cancer types from the most common to the most rare. We discussed advocacy, parenting with cancer, working while having cancer, the role of the caregiver, communicating with your health care team, genetics, personalized medicine, survivorship, clinical trials and many chats on emotional health. We've had guests present on health equity, how to find a clinical trial, how to become a research advocate and so many more. Since 2014, we have highlighted research results presented at the ASCO and SGO annual meetings. And yes, we also spoke about recurrence, the topic that sparked Christina's and my initial Twitter exchange.

Our logo as well as this blog has evolved over the years with our latest version being launched at our 100th Chat in March 2023. 


 

 

Through the years our community has been involved in a number of research efforts. We have been  co-authors on several published research articles covering the needs of women diagnosed with ovarian cancer, caregiver support services, patient needs when considering a PARP inhibitor as well as a number of papers on social media, hashtags and cancer communities.  You may find links to the article on our blog's Publications page.

If you have been a part of the #gyncsm community at any point through the years we would love our feedback by answering these questions:

Question 1 : Approximately how long have you followed the #gyncsm hashtag? What has the cancer community on this platform meant to you?

Question 2: How are you feeling about the cancer community on this platform now? Do you have back-up plans if/when this platform is no longer a good fit for you?

 Question 3: What chat topics have you found most helpful? What topics would you like #gyncsm to cover in future chats?

Feel free to respond in the comment box below or on Twitter https://twitter.com/gyncsm/status/1702737477868417061

It has truly been a wonderful experience working with Christina and all our gyn oncs and supporters. This community has allowed my work as an advocate to grow far greater than I ever imagined. Thanks everyone. 

Dee

Every Day is a Blessing!

Posted by at No comments:
Labels: , , , , , , , , , ,
Subscribe to: Posts (Atom)